Aleksandra V. Zinov'EVa
Research Subjects
Aleksandra V. Zinov'EVa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Natalia A. Gavrilova
Russian University of Medicine
4 shared publications - Denis Nevrov
Ocular Oncology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland
1 shared publication - Dmitry Zaletaev
Research Centre for Medical Genetics, 115522 Moscow, Russia
1 shared publication - E. E. Ioyleva
S. Fyodorov Eye Microsurgery Federal State Institution
1 shared publication Galina Leontyeva
Sci Expt Prod Ltd, Fyodorovs Eye Microsurg Complex, Moscow, Russia
1 shared publication- Konstantin Georgievich Gurevich
Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication
Latest Publications
- Open Access
- 6 April 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (1) , 22-32
Analysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
Currently, there is a wide range of antiglaucoma drugs. Ophthalmologists are faced with the task of choosing certain drugs and their combinations for specific patients. In this regard, studies aimed at studying the effectiveness of treatment, not only in terms of IOP indicators and instrumental research methods, but also in terms of the choice of a particular type of therapy by ophthalmologists, are of great interest. Purpose: to analyze the data obtained in the course of the study of the Russian multicenter scientific program: “Analysis of the assortability of ophthalmologists when choosing therapy within the framework of routine medical care in patients with primary open-angle glaucoma (POAG)”. The large-scale statistical study carried out was based on the study of 197 medical questionnaires from 61 cities of Russia, containing information on 6851 clinical cases. Doctors were asked to fill out a questionnaire based on the results of treatment (at least 2 months), taking into account the following criteria: satisfaction with treatment, adherence to treatment, accessibility, tolerability and ease of use of drugs. Evaluated the use of 5 antiglaucoma drugs of the company Sentiss Russ, belonging to different pharmacological groups: Prolatan (latanoprost), Bimatan (bimatoprost), Brinex-M (brinzolamide); Tisoptan (bimatoprost / timolol maleate), Brinarga (brinzolamide / timolol maleate). During the study, patients were divided into 6 groups depending on the drug used, and also into 3 groups depending on the stage of primary POAG. The data obtained indicate a statically high level of average values when using the point system of all the above criteria when using these drugs. When analyzing the degree of convenience and the level of tolerance of drugs, a tendency towards a decrease in the average scores of these indicators in patients with advanced stage of glaucoma was noted, which may be due to the long-term use of antiglaucoma therapy in this category of patients with changes in the ocular surface. 98.25% of doctors expressed their intention to continue prescribing antiglaucoma drugs from Sentiss Russ.
- 6 April 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (1) , 22-32
Open AccessAnalysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
Currently, there is a wide range of antiglaucoma drugs. Ophthalmologists are faced with the task of choosing certain drugs and their combinations for specific patients. In this regard, studies aimed at studying the effectiveness of treatment, not only in terms of IOP indicators and instrumental research methods, but also in terms of the choice of a particular type of therapy by ophthalmologists, are of great interest. Purpose: to analyze the data obtained in the course of the study of the Russian multicenter scientific program: “Analysis of the assortability of ophthalmologists when choosing therapy within the framework of routine medical care in patients with primary open-angle glaucoma (POAG)”. The large-scale statistical study carried out was based on the study of 197 medical questionnaires from 61 cities of Russia, containing information on 6851 clinical cases. Doctors were asked to fill out a questionnaire based on the results of treatment (at least 2 months), taking into account the following criteria: satisfaction with treatment, adherence to treatment, accessibility, tolerability and ease of use of drugs. Evaluated the use of 5 antiglaucoma drugs of the company Sentiss Russ, belonging to different pharmacological groups: Prolatan (latanoprost), Bimatan (bimatoprost), Brinex-M (brinzolamide); Tisoptan (bimatoprost / timolol maleate), Brinarga (brinzolamide / timolol maleate). During the study, patients were divided into 6 groups depending on the drug used, and also into 3 groups depending on the stage of primary POAG. The data obtained indicate a statically high level of average values when using the point system of all the above criteria when using these drugs. When analyzing the degree of convenience and the level of tolerance of drugs, a tendency towards a decrease in the average scores of these indicators in patients with advanced stage of glaucoma was noted, which may be due to the long-term use of antiglaucoma therapy in this category of patients with changes in the ocular surface. 98.25% of doctors expressed their intention to continue prescribing antiglaucoma drugs from Sentiss Russ.
- Open Access
- 1 October 2021
- Published by LLC MedTestInfo in Человек и его здоровье
- Vol. 24 (2) , 37-45
Analysis of retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function following exposure of the retina to 577 nm wavelength laser light in continuous mode
Objective. The aim of the study was to investigate the retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function after exposure of the retina to 577 nm laser light in a continuous mode in experimental conditions after intravitreal injection of VEGF165 (Vascular endothelial growth factor). Materials and methods. The study was performed on 4-5 week old male C57BL / 6J mice. 4 groups, 5 mice in each, were formed, one animal eye was experimental and the second remained intact. The animals of the first group received intravitreal injection of phosphate-buffered saline (PBS); animals in the second, third and fourth groups received intravitreal injection of 50 ng/ml of recombinant VEGF165; in the third and fourth groups, one day after the VEGF165 intravitreal administration, laser irradiation with a wavelength of 577 nm was performed on the retina in micropulse and continuous modes, respectively. Tissue samples from animals of the first and second groups were taken 2 days after PBS and VEGF165 administration, and in animals from the third and fourth groups one day after laser exposure to the retina. Results. Retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function as a result of retinal exposure to 577 nm laser radiation in continuous mode following intravitreal injection of VEGF165 was studied. Genes with significant changes in expression levels were identified (genes that regulate the processes of angiogenesis). Conclusion. Understanding the mechanisms of modulation of retinal gene expression may help to identify the key regulatory factors providing therapeutic effects of laser radiation in continuous and micropulsed modes and provide the basis for future therapeutic tactics for retinal diseases.
- 1 October 2021
- Published by LLC MedTestInfo in Человек и его здоровье
- Vol. 24 (2) , 37-45
Open AccessAnalysis of retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function following exposure of the retina to 577 nm wavelength laser light in continuous mode
Objective. The aim of the study was to investigate the retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function after exposure of the retina to 577 nm laser light in a continuous mode in experimental conditions after intravitreal injection of VEGF165 (Vascular endothelial growth factor). Materials and methods. The study was performed on 4-5 week old male C57BL / 6J mice. 4 groups, 5 mice in each, were formed, one animal eye was experimental and the second remained intact. The animals of the first group received intravitreal injection of phosphate-buffered saline (PBS); animals in the second, third and fourth groups received intravitreal injection of 50 ng/ml of recombinant VEGF165; in the third and fourth groups, one day after the VEGF165 intravitreal administration, laser irradiation with a wavelength of 577 nm was performed on the retina in micropulse and continuous modes, respectively. Tissue samples from animals of the first and second groups were taken 2 days after PBS and VEGF165 administration, and in animals from the third and fourth groups one day after laser exposure to the retina. Results. Retinal expression of genes involved in the regulation of angiogenesis and endothelial barrier function as a result of retinal exposure to 577 nm laser radiation in continuous mode following intravitreal injection of VEGF165 was studied. Genes with significant changes in expression levels were identified (genes that regulate the processes of angiogenesis). Conclusion. Understanding the mechanisms of modulation of retinal gene expression may help to identify the key regulatory factors providing therapeutic effects of laser radiation in continuous and micropulsed modes and provide the basis for future therapeutic tactics for retinal diseases.
- Open Access
- 27 May 2020
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 13 (2) , 83-87-87
Amiodarone-associated optic neuropathy in the treatment of cardiovascular diseases
An increase in the growth of cardiovascular diseases has been observed in the last few years. Cardiac rhythm disturbances, especially atrial fibrillation, in absence of cardioversion and proper prophylaxis lead to thromboembolic complications. Drug therapy in rhythm disorders consists of the many antiarrhythmic drugs, prescribed for a long period of time. This fact can result to the ocular toxicy, which have insidious and slow progression. First and foremost, there is a risk of amiodarone-associated toxicity. Amiodarone affects as anterior segment structures (photosensitivity, corneal and conjunctiva deposits, anterior subcapsular cataract) as posterior segment structures (optic neuropathy). Fibers of the papillomacular bundle are the most vulnerable structures in optic nerve to the toxic effect of amiodarone due to the absence of myelination and salutatory conduction, their small size and high-energy requirements. The difficulties in diagnosis of amiodarone-associated optic neuropathy are related to slow progression (patients don’t notice symptoms until the late stages) and clinical similarity to ischemic optic neuropathy.
- 27 May 2020
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 13 (2) , 83-87-87
Open AccessAmiodarone-associated optic neuropathy in the treatment of cardiovascular diseases
An increase in the growth of cardiovascular diseases has been observed in the last few years. Cardiac rhythm disturbances, especially atrial fibrillation, in absence of cardioversion and proper prophylaxis lead to thromboembolic complications. Drug therapy in rhythm disorders consists of the many antiarrhythmic drugs, prescribed for a long period of time. This fact can result to the ocular toxicy, which have insidious and slow progression. First and foremost, there is a risk of amiodarone-associated toxicity. Amiodarone affects as anterior segment structures (photosensitivity, corneal and conjunctiva deposits, anterior subcapsular cataract) as posterior segment structures (optic neuropathy). Fibers of the papillomacular bundle are the most vulnerable structures in optic nerve to the toxic effect of amiodarone due to the absence of myelination and salutatory conduction, their small size and high-energy requirements. The difficulties in diagnosis of amiodarone-associated optic neuropathy are related to slow progression (patients don’t notice symptoms until the late stages) and clinical similarity to ischemic optic neuropathy.
- 1 September 2019
- Published by SLACK, Inc. in Journal of Refractive Surgery
- Vol. 35 (9) , 606-609
Simultaneous Implantation of Refractive Lenticule and Intracorneal Ring Segment in the Management of Pellucid Marginal Degeneration
PURPOSE: To describe a patient with pellucid macular degeneration suffering from visual deterioration due to high irregular astigmatism and intolerant to contact lenses, who underwent a new surgical procedure that combined intrastromal lamellar keratoplasty and a 359° intracorneal ring segment implantation, enabling both ametropia and corneal thinning correction. METHODS: Case report. RESULTS: Refractive lenticule obtained during a myopic small incision lenticule extraction procedure was used as the donor lamellar graft. The technique described allowed for partial cylinder reduction and reinforcement of the thinned cornea. Uncorrected distance visual acuity improved from 0.02 to 0.5 (decimal) and corrected distance visual acuity improved from 0.4 to 0.7 with a decrease of 4.50 diopters in corneal astigmatism. CONCLUSIONS: Despite the lack of long-term observation, the new technique described in this case report was successful for this specific patient and therefore might be effective and safe in severe stages of disease. [ J Refract Surg. 2019;35(9):606–609.]
- 1 September 2019
- Published by SLACK, Inc. in Journal of Refractive Surgery
- Vol. 35 (9) , 606-609
Simultaneous Implantation of Refractive Lenticule and Intracorneal Ring Segment in the Management of Pellucid Marginal Degeneration
PURPOSE: To describe a patient with pellucid macular degeneration suffering from visual deterioration due to high irregular astigmatism and intolerant to contact lenses, who underwent a new surgical procedure that combined intrastromal lamellar keratoplasty and a 359° intracorneal ring segment implantation, enabling both ametropia and corneal thinning correction. METHODS: Case report. RESULTS: Refractive lenticule obtained during a myopic small incision lenticule extraction procedure was used as the donor lamellar graft. The technique described allowed for partial cylinder reduction and reinforcement of the thinned cornea. Uncorrected distance visual acuity improved from 0.02 to 0.5 (decimal) and corrected distance visual acuity improved from 0.4 to 0.7 with a decrease of 4.50 diopters in corneal astigmatism. CONCLUSIONS: Despite the lack of long-term observation, the new technique described in this case report was successful for this specific patient and therefore might be effective and safe in severe stages of disease. [ J Refract Surg. 2019;35(9):606–609.]
- 1 August 2019
- Published by Elsevier in Experimental Eye Research
- Vol. 185, 107650
Molecular genetic mechanisms of influence of laser radiation with 577 nm wavelength in a microimpulse mode on the condition of the retina
- 1 August 2019
- Published by Elsevier in Experimental Eye Research
- Vol. 185, 107650
Molecular genetic mechanisms of influence of laser radiation with 577 nm wavelength in a microimpulse mode on the condition of the retina